Document 0842
 DOCN  M9440842
 TI    Improved immunogenicity of recombinant vaccinia virus-anchored gp120
       lacking gp41.
 DT    9404
 AU    Jin Y; Giri C; Klutch MJ; Shepp D; Wright SE; Department of Internal
       Medicine, Texas Tech University Health; Sciences Center.
 SO    Vaccine. 1993 Oct;11(13):1280-2. Unique Identifier : AIDSLINE
       MED/94127076
 AB    To produce a vaccine against human immunodeficiency virus-1 with
       improved immunogenicity, the transmembrane and cytoplasmic tail regions
       of human immunodeficiency virus-1 were replaced with those of the
       Vesicular Stomatitis Virus glycoprotein, and cloned into vaccinia virus.
       This recombinant vaccinia virus, vvE13, was compared to one expressing
       full length envelope gp160, vvE1. Env products of both were located on
       the cell surface. Antibody response, lymphocyte proliferation and
       cytotoxicity were better with vvE13 than with vvE1 inoculated mice.
 DE    Animal  Cell Division/PHYSIOLOGY  Comparative Study  HIV Envelope
       Protein gp120/*GENETICS/*IMMUNOLOGY  HIV Envelope Protein
       gp41/*GENETICS/*IMMUNOLOGY  Mice  Mice, Inbred BALB C  Support, Non-U.S.
       Gov't  Support, U.S. Gov't, Non-P.H.S.  Vaccines,
       Synthetic/IMMUNOLOGY/PHARMACOLOGY  Vaccinia Virus/*GENETICS/*IMMUNOLOGY
       Vesicular Stomatitis-Indiana Virus/GENETICS  Viral Envelope
       Proteins/GENETICS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).